Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer

NCT03367741 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03367741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03367741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 16, 2018
Completion date
July 23, 2027
Enrollment
82 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial carcinoma, metastatic endometrial carcinoma, recurrent endometrial carcinoma, stage iii uterine corpus carcinoma or carcinosarcoma ajcc v8, stage iv uterine corpus carcinoma or carcinosarcoma ajcc v8